scholarly journals Serum Metabolomic Response to Long-Term Supplementation withall-rac-α-Tocopheryl Acetate in a Randomized Controlled Trial

2016 ◽  
Vol 2016 ◽  
pp. 1-7 ◽  
Author(s):  
Alison M. Mondul ◽  
Steven C. Moore ◽  
Stephanie J. Weinstein ◽  
Anne M. Evans ◽  
Edward D. Karoly ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin E ◽  
Cancer Prevention ◽  
Controlled Trial ◽  
Prostate Cancer Risk ◽  
Alpha Tocopherol ◽  
Tocopheryl Acetate ◽  
Metabolite Level ◽  
Randomized Controlled ◽  
Atbc Study

Background. The Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, a randomized controlled cancer prevention trial, showed a 32% reduction in prostate cancer incidence in response to vitamin E supplementation. Two other trials were not confirmatory, however.Objective. We compared the change in serum metabolome of the ATBC Study participants randomized to receive vitamin E to those who were not by randomly selecting 50 men from each of the intervention groups (50 mg/day all-rac-α-tocopheryl acetate (ATA), 20 mg/dayβ-carotene, both, placebo).Methods. Metabolomic profiling was conducted on baseline and follow-up fasting serum (Metabolon, Inc.).Results. After correction for multiple comparisons, five metabolites were statistically significantly altered (βis the change in metabolite level expressed as number of standard deviations on the log scale):α-CEHC sulfate (β=1.51,p=1.45×10-38),α-CEHC glucuronide (β=1.41,p=1.02×10-31),α-tocopherol (β=0.97,p=2.22×10-13),γ-tocopherol (β=-0.90,p=1.76×10-11), andβ-tocopherol (β=-0.73,p=9.40×10-8). Glutarylcarnitine, beta-alanine, ornithine, and N6-acetyllysine were also decreased by ATA supplementation (βrange 0.40 to −0.36), but not statistically significantly.Conclusions. Comparison of the observed metabolite alterations resulting from ATA supplementation to those in other vitamin E trials of different populations, dosages, or formulations may shed light on the apparently discordant vitamin E-prostate cancer risk findings.

scholarly journals Family history of prostate cancer and prostate cancer risk in the Alpha‐Tocopherol, Beta‐Carotene Cancer Prevention (ATBC) Study

2008 ◽  
Vol 123 (5) ◽  
pp. 1154-1159 ◽  
Author(s):  
Jiyoung Ahn ◽  
Roxana Moslehi ◽  
Stephanie J. Weinstein ◽  
Kirk Snyder ◽  
Jarmo Virtamo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prostate Cancer Risk ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
History Of ◽  
Atbc Study

scholarly journals Serum Metabolomic Response to Low and High Dose Vitamin E Supplementation in Two Randomized Controlled Trials

2020 ◽  
Vol 4 (Supplement_2) ◽  
pp. 1810-1810
Author(s):  
Jiaqi Huang ◽  
Stephanie Weinstein ◽  
Wendy Mack ◽  
Howard Hodis ◽  
Demetrius Albanes
Keyword(s):  
Prostate Cancer ◽  
Vitamin E ◽  
Cancer Prevention ◽  
Low Dose ◽  
Alpha Tocopherol ◽  
P Value ◽  
High Dose ◽  
Atbc Study ◽  
High Dose Vitamin ◽  
Vitamin E Supplementation

Abstract Objectives Vitamin E is an essential micronutrient and critical human antioxidant that has been tested for cancer and cardiovascular preventative effects for decades with conflicting results. For example, prostate cancer incidence was reduced by a low-dose vitamin E supplement in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study, but the findings were not replicated by high-dose vitamin E trials such as the Selenium and Vitamin E Cancer Prevention Trial (SELECT). The present investigation examined the serum metabolomic responses to low- and high-dose vitamin E supplementation in order to gain biological insight into the divergent trial outcomes. Methods We examined baseline and on-study serum samples for 154 men randomly assigned to receive 400 IU vitamin E (as alpha-tocopheryl acetate; ATA) or placebo daily in the Vitamin E Atherosclerosis Prevention Study (VEAPS), and 100 men administered 50 IU ATA or placebo daily in the ATBC Study. Over 970 known metabolites were identified using an ultrahigh-performance LC-MS/MS platform. Linear regression models estimated the change in serum metabolites of men supplemented with vitamin E to those assigned to placebo in VEAPS compared with ATBC. Results Serum alpha-carboxyethyl hydrochroman (CEHC) sulfate, alpha-tocopherol, and beta-/gamma-tocopherol were significantly altered by supplementation with ATA in both the VEAPS and ATBC trials (all P-values ≤ 5.1 × 10−5, the Bonferroni multiple-comparisons corrected statistical threshold). Serum C22 lactone sulfate was also significantly decreased in response to the high-dose vitamin E supplement in VEAPS (β = −0.70, P-value = 8.1 × 10−6), but not altered in the low-dose ATBC trial (β = −0.17, P-value = 0.4). Additionally, changes in several androgenic steroid metabolites were strongly related to the vitamin E supplement-associated change in C22 lactone sulfate only in the high-dose VEAPS trial. Conclusions We found evidence of a dose-dependent vitamin E supplementation effect on a novel C22 lactone sulfate compound as well as several androgenic steroids that may have relevance to previous controlled trial findings for prostate cancer. Funding Sources This research was supported by the Intramural Research Program of the National Cancer Institute, National Institutes of Health, U.S. Public Health Service, Department of Health and Human Services.

scholarly journals Vitamin E and the risk of pneumonia: using the I2 statistic to quantify heterogeneity within a controlled trial

2016 ◽  
Vol 116 (9) ◽  
pp. 1530-1536 ◽  
Author(s):  
Harri Hemilä
Keyword(s):  
Vitamin E ◽  
Cancer Prevention ◽  
Treatment Effect ◽  
Leisure Time ◽  
Controlled Trial ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
Nutritional Epidemiology ◽  
Atbc Study ◽  
Vitamin E Supplementation

AbstractAnalyses in nutritional epidemiology usually assume a uniform effect of a nutrient. Previously, four subgroups of the Alpha-Tocopherol, Beta-Carotene Cancer Prevention (ATBC) Study of Finnish male smokers aged 50–69 years were identified in which vitamin E supplementation either significantly increased or decreased the risk of pneumonia. The purpose of this present study was to quantify the level of true heterogeneity in the effect of vitamin E on pneumonia incidence using the I2 statistic. The I2 value estimates the percentage of total variation across studies that is explained by true differences in the treatment effect rather than by chance, with a range from 0 to 100 %. The I2 statistic for the effect of vitamin E supplementation on pneumonia risk for five subgroups of the ATBC population was 89 % (95 % CI 78, 95 %), indicating that essentially all heterogeneity was true variation in vitamin E effect instead of chance variation. The I2 statistic for heterogeneity in vitamin E effects on pneumonia risk was 92 % (95 % CI 80, 97 %) for three other ATBC subgroups defined by smoking level and leisure-time exercise level. Vitamin E decreased pneumonia risk by 69 % among participants who had the least exposure to smoking and exercised during leisure time (7·6 % of the ATBC participants), and vitamin E increased pneumonia risk by 68 % among those who had the highest exposure to smoking and did not exercise (22 % of the ATBC participants). These findings refute there being a uniform effect of vitamin E supplementation on the risk of pneumonia.

scholarly journals Metabolomic analysis of prostate cancer risk in a prospective cohort: The alpha‐tocopherol, beta‐carotene cancer prevention (ATBC) study

2015 ◽  
Vol 137 (9) ◽  
pp. 2124-2132 ◽  
Author(s):  
Alison M. Mondul ◽  
Steven C. Moore ◽  
Stephanie J. Weinstein ◽  
Edward D. Karoly ◽  
Joshua N. Sampson ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prospective Cohort ◽  
Prostate Cancer Risk ◽  
Beta Carotene ◽  
Alpha Tocopherol ◽  
Metabolomic Analysis ◽  
Atbc Study

scholarly journals Plasma Vitamin D and Prostate Cancer Risk: Results from the Selenium and Vitamin E Cancer Prevention Trial

2014 ◽  
Vol 23 (8) ◽  
pp. 1494-1504 ◽  
Author(s):  
Alan R. Kristal ◽  
Cathee Till ◽  
Xiaoling Song ◽  
Catherine M. Tangen ◽  
Phyllis J. Goodman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Vitamin D ◽  
Vitamin E ◽  
Cancer Risk ◽  
Cancer Prevention ◽  
Prostate Cancer Risk ◽  
Prevention Trial ◽  
Plasma Vitamin

scholarly journals Prevention of Prostate Cancer: Outcomes of Clinical Trials and Future Opportunities

2014 ◽  
pp. e76-e80 ◽  
Author(s):  
Ian Thompson ◽  
Alan Kristal ◽  
Elizabeth A. Platz
Keyword(s):  
Prostate Cancer ◽  
Clinical Trial ◽  
Overall Survival ◽  
Cancer Prevention ◽  
Weight Control ◽  
Prostate Cancer Risk ◽  
Alpha Tocopherol ◽  
Prevention Trial ◽  
Low Grade ◽  
Prostate Cancer Prevention

Prostate cancer is an excellent target for prevention, to reduce both mortality and the burden of overdetection of potential inconsequential disease whose diagnosis increases cost, morbidity, and anxiety. The Prostate Cancer Prevention Trial has demonstrated that finasteride significantly reduces the risk of prostate cancer but only low-grade disease; overall survival is unaffected. In the Selenium and Vitamin E Cancer Prevention Trial (SELECT) clinical trial, selenium had no effect on prostate cancer risk, but alpha tocopherol significantly increased the risk by 17%. The most promising future approaches to prostate cancer prevention will likely focus on nutrition, especially weight control, and through modulation of inflammation.

Sign in / Sign up

Export Citation Format

Share Document